

Addressing the Opioid Epidemic

Naloxone and its Role in Prevention of Opioid Overdose Death

May 24, 2018



Quality Improvement Organizations

Sharing Knowledge. Improving Health Care.
CENTERS FOR MEDICARE & MEDICAID SERVICES

Great Plains



Quality Innovation Network

Five Pillars



EDUCATION



PRESCRIPTION DRUG
MONITORING PROGRAM




TAKE BACK PROGRAM



TREATMENT



LAW ENFORCEMENT



Today's Speaker

Elizabeth Skoy, PharmD

Associate Professor of Pharmacy Practice

North Dakota State University School of Pharmacy

Fargo, ND



Naloxone and its Role in Prevention of Opioid Overdose Death

ELIZABETH SKOY, PHARM.D., RPH

ASSOCIATE PROFESSOR

NORTH DAKOTA STATE UNIVERSITY SCHOOL OF PHARMACY

Objectives

Describe naloxone and its role in preventing death related to opioid overdose

Identify individuals who may benefit from possessing naloxone

Describe and differentiate between available naloxone dosage forms

Pathophysiology of Opioid Overdose

Opioid Receptors

- **Mu**, delta, kappa

Opioid Receptor Effects

- Pain
- Opioid dependence
- Respiration
- Gastrointestinal tract

Opioid Overdose Triad

- Pinpoint Pupils
- Unconscious
- Difficulty breathing

Risk Factors for Opioid Overdose

High Dose Opioids

- 50 MME
- 100 MME

Use of opioid with another sedating substance

- Benzodiazepine
- Sleep aid
- Alcohol


Antidepressant use

Age

Underlying respiratory conditions

- COPD, Sleep Apnea, Asthma

Naloxone: Mechanism of Action



<http://www.penington.org.au/>

Naloxone Education Pearls

Should always include two doses

- Administer second dose in 2 to 3 minutes if no response

If overdose is not present does not elicit a response

Adverse effect: withdrawal

Viewed as a safety measure: seatbelt, fire extinguisher

Naloxone Education Pearls

Education to caregiver

Good Samaritan Law

Apps or resources

- Brochures
- Product information
- Apps (OpiRescue App)

Naloxone Dosage Forms

Injectable (generic)

- 0.4 mg/mL (single dose or multidose vials)
- Inject 1 mL intramuscularly
- Dispense with 23-25 gauge 3mL syringe



Intranasal (generic)

- 1 mg/mL
- Spray 1 mL (1/2 of syringe) into each nostril
- Prefilled glass syringe
- Dispense with mucosal atomizer device



Naloxone Dosage Forms

Intranasal (Narcan Nasal)

- 4 mg/0.1 mL
- Spray one device into nostril
- Designed for “layperson”
- Excursions 38–104° F



Auto-injector (Evzio)

- 0.4 mg/0.4 mL
- Inject into outer thigh as directed by voice
- Designed for “layperson”
- Excursions 38–104° F



Opioid Overdose Response

Recognize overdose

Call 911

Perform rescue breathing

Give naloxone

Place in a recovery position

Repeat dose in 2 to 3 minutes if no response

Naloxone Availability

Medical Provider

Pharmacist

- Statewide protocol
- Collaborative practice agreement

Considerations

- Third party prescribing
- Payment
- Co-prescribing (prescriber or opioid)
- Pharmacist dispensing upon medication review

Naloxone in Communities

Stigma reduction

Training and education for providers and pharmacists

Liability concerns

Perpetuating the problem? – NO

- Decreases overdose death
- Number of overdoses decrease

Seal et al. J Urban Health. 2005; 82.

Walley et al. BMJ.2013; 346.

Davis CS, et al. Subst Abus. 2016.

Questions



Medication Safety LAN

Upcoming Events

- Recordings of previous webinars available at <http://greatplainsqin.org/initiatives/medication-safety/>

Contact Information

Beth Nech, MA

Project Manager

bnech@kfmc.org

Kansas Foundation for Medical Care

800 SW Jackson St, Ste 700

Topeka, KS 66612

P: 785.271.4120

Paula Sitzman, RN, BSN

Quality Improvement Advisor

paula.sitzman@area-a.hcqis.org

Tammy Baumann RN, LSSGB

Quality Improvement Advisor

tammy.baumann@area-a.hcqis.org

Great Plains QIN - Nebraska

1200 Libra Drive, Suite 102

Lincoln, Nebraska 68512

P: 402.476.1399

Sally May, RN, BSN, CH-GCN

Senior Quality Improvement Specialist

sally.may@area-a.hcqis.org

Jayme Steig, PharmD, RPh

Quality Improvement Program Manager

jayme.steig@area-a.hcqis.org

Quality Health Associates of North Dakota

41 36th Ave NW

Minot, ND 58703

P: 701.989.6220

Linda Penisten, RN, OTR/L

Program Manager

linda.penisten@area-a.hcqis.org

South Dakota Foundation for Medical Care

2600 West 49th Street, Suite 300

Sioux Falls, SD 57105

P: 605-444-4124